C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/26/26
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 02/23/26
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewsWire • 02/04/26
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysGlobeNewsWire • 01/14/26
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewsWire • 11/25/25
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • 11/06/25
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/06/25
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 10/01/25
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual MeetingGlobeNewsWire • 09/20/25
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual MeetingGlobeNewsWire • 09/03/25
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/07/25
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/07/25
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/07/25
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/07/25